ArticleJournal of gastroenterology2026
Clinical significance of comprehensive genomic profiling in unresectable or recurrent gastrointestinal stromal tumors: a multicenter retrospective cohort study.
Article in Journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dedifferentiated Gastric Gastrointestinal Stromal Tumor with Rapid Growth Mimicking Other Malignancies: A Case Report.Surgical case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTyrosine kinase inhibitors (TKIs) targeting KIT and PDGFRA mutations are the mainstay of treatment for gastrointestinal stromal tumors (GISTs). Comprehensive genomic profiling (CGP) has recently been incorporated into routine practice for various solid tumors, facilitating personalized treatment strategies. We elucidated the current status and clinical significance of CGP in patients with advanced GISTs.
methodsIn this multicenter retrospective cohort study, we analyzed 36 patients with unresectable or recurrent GISTs who underwent CGP testing between November 2019 and February 2025. Specimen details, genomic alterations, expert panel assessments, and treatment implementations were collected. Turnaround time and overall survival (OS) were evaluated.
resultsAmong the patients, 75% underwent CGP during or post-third-line treatment. Actionable and druggable alterations were identified in 97.2% and 52.8%, respectively. Expert panel-recommended treatment was proposed for 12 patients (33.3%); however, only one received CGP-guided therapy. The median turnaround time and OS from CGP were 63 days (range, 41-100) and 19.9 months (range, 0.8-68.0), respectively. Most patients were microsatellite-stable with low tumor mutational burden. Among non-KIT genes, CDKN2A and CDKN2B alterations were the most frequently identified. Furthermore, patients harboring these alterations showed poorer OS post-recurrence (CDKN2A: HR 3.09, 95% CI 1.17-8.18, p = 0.017; CDKN2B: HR 2.55, 95% CI 0.86-8.18, p = 0.081).
conclusionsCGP revealed actionable alterations in most patients with advanced GISTs; however, its impact on treatment decisions remains limited under current practice. Early CGP implementation may facilitate access to matched therapies or clinical trials, enabling prognostic stratification in patients with advanced GISTs.
Indexed as
Identifiers
41266846What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.